Establishing new detection procedure and elucidation of clinical significance in lung carcinoma with low-frequency EGFR T790M mutation

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16336
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50010:Tumor biology-related
• Research Institution: Nagoya City University
• Principal Investigator: Tatematsu Tsutomu 名古屋市立大学, 医薬学総合研究院(医学), 講師 (40721874)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: T790M / EGFR / lung carcinoma

Outline of Final Research Achievements

We investigated low-frequency T790M mutation about 210 EGFR-mutated lung cancer patients untreated by EGFR-TKI. The incidence of T790M mutation was analyzed using CAST-PCR which can detect low-frequency T790M mutation. T790M mutations were detected in 66(31.4%) of the 210 cases. There were no significant difference about OS and RFS according to the T790M mutation status. It was shown that low-frequency pretreatment T790M mutation dose not affect the prognosis of EGFR-mutated lung cancer patients.

Free Research Field

呼吸器外科

Academic Significance and Societal Importance of the Research Achievements

一般的なPCRで検出できなかった微量T790M変異をCAST-PCRで検出しえた。T790M変異を有する症例は31.4％に認め、比較的多いことが判明した。EGFR遺伝子変異陽性肺癌の最適な薬物治療を検討する上で重要なデータであり学術的意義があると考える。より微量な遺伝子変異を検索実際の臨床で第1～3世代のどのEGFR-TKI（第1-3世代）の選択する際に重要なデータになりうる。